Print Page     Close Window     

SEC Filings

6-K
AC IMMUNE SA filed this Form 6-K on 06/28/2017
Entire Document
 
 

© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 11 TDP - 43 α - synuclein Tau Abeta Neurodegenerative diseases share MoA and targets Additional value from leveraging therapies into neuro - orphan indications ▪ Parkinson’s disease ▪ Dementia with Lewy bodies ▪ Alzheimer’s disease ▪ Down syndrome ▪ Progressive supranuclear palsy (PSP) ▪ Frontotemporal dementia ( FTD) ▪ Frontotemporal lobar degeneration High value of neuro - orphan diseases ▪ Provide faster path to approval with lower R&D spend ▪ Patient identification and effect size may increase by focusing on genetically defined diseases ▪ Represent lower risk route for entry into the neurodegenerative space ▪ Cerebral amyloid angiopathy ▪ Chronic traumatic encephalopathy ▪ Amyotrophic lateral sclerosis ▪ Corticobasal degeneration ▪ Pick’s disease ▪ Amyotrophic lateral sclerosis ▪ Myotonic dystrophy

 

© AC Immune 2015